glp-1 gastroparesis class action in michigan semaglutide law office michigan digestive blockage law firm Ozempic Lawsuit: May 2026 Blindness and Gastroparesis Claims-mvanhaasteren.nl Ozempic® Lawsuit | July 2026

Last week, Eli Lillys orforglipron has become the first oral, non-peptide GLP-1 receptor agonist to clear a Phase 3 trial, showing strong efficacy in reducing A1C (up to 1.6%) and body weight (up to 7.9%) in people with type 2 diabetes

Glucagon-like peptide-1 (GLP-1) receptor agonists have drawn a lot of interest lately for their therapeutic advantages over controlling blood sugar levels in the management of type 2 diabetes mellitus (T2DM)

Affordable Solution: At just $60 per month, Trimova provides a cost-effective alternative to expensive weight loss medications, making it accessible to more people

Learn what this looks like.

A study of nearly 1.1 million people found that semaglutide (the drug in Ozempic and Wegovy) was associated with a 40-70% lower risk of developing Alzheimer's compared to other diabetes medications